CN Patent

CN107569678B — 利拉鲁肽在制备治疗急慢性移植排斥反应药物中的应用

Assigned to Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology · Expires 2020-10-30 · 6y expired

What this patent protects

本发明涉及利拉鲁肽在制备治疗急慢性移植排斥反应药物中的应用。利拉鲁肽能通过降低效应T细胞活性来延长移植受体的存活时间，并且下调黏附分子表达，抑制炎性浸润，抑制内皮向间质转化。从而改善移植物血管病及移植后纤维化进展。

USPTO Abstract

本发明涉及利拉鲁肽在制备治疗急慢性移植排斥反应药物中的应用。利拉鲁肽能通过降低效应T细胞活性来延长移植受体的存活时间，并且下调黏附分子表达，抑制炎性浸润，抑制内皮向间质转化。从而改善移植物血管病及移植后纤维化进展。

Drugs covered by this patent

Patent Metadata

Patent number
CN107569678B
Jurisdiction
CN
Classification
—
Expires
2020-10-30
Drug substance claim
No
Drug product claim
No
Assignee
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.